Perakizumab, a novel drug the developers, offers a exciting step in the management against several scarring diseases. Unlike existing therapies, this agent carefully targets and TGF-beta signaling, a critical process in the development of scar tissue formation. Early patient trials suggest a posi… Read More

Bivatuzumab BIWA 4: A New Treatment Approach Bivatuzumab BIWA 4 is a unique clinical candidate for treating specific cancers. This antibody uniquely binds a key protein associated in malignant development and metastasis. Early preliminary findings indicate promise … Read More